In this report we examine candidate pathways perturbed by Compound Kushen Injection (CKI) a Traditional Chinese Medicine (TCM) that we have previously shown to alter the gene expression patterns of multiple pathways and induce apoptosis in cancer cells. We have measured protein levels in HEPG2 and MDA-MB-231 cells for genes in the cell cycle pathway, DNA repair pathway and DNA double strand breaks (DSBs) previously shown to have altered expression by CKI. We have also examined energy metabolism by measuring [ADT]/[ATP] ratio (cell energy charge), lactate production and glucose consumption. Our results demonstrate that CKI can suppress protein levels for cell cycle regulatory proteins and DNA repair while increasing the level of DSBs. We also show that energy metabolism is reduced based on reduced glucose consumption and reduced cellular energy charge. Our results validate these pathways as important targets for CKI. We also examined the effect of the major alkaloid component of CKI, oxymatrine and determined that it had no effect on DSBs, a small effect on the cell cycle and increased the cell energy charge. Our results indicate that CKI likely acts through the effect of multiple compounds on multiple targets where the observed phenotype is the integration of these effects and synergistic interactions.
1

Introduction
2
Compound Kushen Injection (CKI) is a complex mixture of plant bioactives extracted from Kushen 3 (Sophora flavescens) and Baituling (Smilax Glabra) that has been approved for use in China since 4 1995 by the State Food and Drug Administration (SFDA) of China (State medical license no. 5 Z14021231). CKI is widely used in China as an adjunct for both radiotherapy and chemotherapy in 6
cancer. While most of the data supporting its use have been anecdotal and there is little clinical trial 7 data demonstrating its efficacy, it has been shown to be effective at reducing sarcoma growth and 8 cancer pain in an animal model [1] and cancer pain in patients [2] .
9
CKI contains over 200 chemical compounds including alkaloids and flavonoids such as matrine, 10 oxymatrine and kurarinol, and has previously been shown to affect the cell cycle and induce 11 apoptosis in cancer cells [1, 2, 3, 4, 5, 6, 7] . Furthermore, functional genomic characterisation of the 12 effect of CKI on cancer cells using transcriptome data indicated that multiple pathways were most 13 likely affected by CKI [4] . These observations support a model wherein many/all of the individual 14 compounds present in CKI can act on many single targets or on multiple targets to induce apoptosis. 15 Based on previously reported work [4] and our currently unpublished work (Cui et al ) [8] , specific 16 pathways were selected for follow up experiments to validate their response to CKI in order to 17 formulate more specific hypotheses regarding the mechanism of action of CKI on cancer cells. We 18 had previously shown that CKI altered the cell cycle and induced apoptosis while altering the 19 expression of many cell cycle genes in three cancer cell lines [4, 8] . We had also shown that DNA 20 repair pathway genes were significantly down-regulated by CKI and that energy production related 21 to NAD(P)H synthesis from glycolysis and oxidative phosphorylation was reduced by CKI. As a 22 result we focused on the following candidate pathways: cell cycle, DNA repair and glucose 23 metabolism to validate their alteration by CKI. We used two cell lines for these validation 24 experiments, one relatively insensitive to CKI (MDA-MB-231) and one sensitive to CKI (HEPG2). 25 Furthermore, while the literature shows varying effects for major compounds present in CKI on 26 cancer cells [9, 10], we also tested oxymatrine, the major alkaloid found in CKI and widely believed 27 to be very important for the effects of CKI, on our selected pathways.
28
Materials and methods
29
Cell culture and chemicals
30
CKI with a total alkaloid concentration of 26.5 mg/ml in 5 ml ampoules was provided by Zhendong 31 Pharmaceutical Co. Ltd. (Beijing, China). Cell culture methods have been previously described [4] . 32 A human breast adenocarcinoma cell line, MDA-MB-231 and a hepatocellular carcinoma cell line 33 HEPG2 were purchased from American Type Culture Collection (ATCC, Manassas, VA). The cells 34 were cultured in Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, MA, USA) 35 supplemented with 10% foetal bovine serum (Thermo Fisher Scientific). Both cell lines were cultured 36 at 37℃ with 5% CO2. For all in vitro assays, cells were cultured overnight before being treated with 37 either CKI (at 1 mg/ml and 2 mg/ml of total alkaloids). As a negative control, cells were treated 38 with medium only and labelled as "untreated". After 24 and 48 hours of treatment, cells were 39 harvested and subjected to the downstream experiments.
40
All the in vitro assays employed either 6-well plates or 96-well plates. The seeding density for 41 6-well plates for both cell lines was 4×10 5 cells and treatment methods were as previously described 42 [4] . manufacturer.
72
Cell cycle assay
73
Cells were cultured in 6-well plates and treated with 2 mg/ml CKI or 0.5 mg/ml oxymatrine. After 74 culturing for 3, 6, 12, 24 and 48 hours, cells were harvested and subjected to cell cycle analysis by
75
Propidium Iodide staining as previously reported [4] . Data were obtained by flow cytometry using 76 Accrui (BD Biosciences, NJ, US) and analysed using FlowJo software (Tree Star Inc, Ashland,
77
Oregon, USA). Biosciences, NJ, US), and the data were analysed using FlowJo (Tree Star Inc.) software.
105
Cell cycle functional enrichment re-analysis
106
In order to identify the phases of the cell cycle affected by CKI, differentially expressed gene data 107 from [4] was submitted to the Reactome database [11] , and used to identify functionally enriched 108 genes.
Statistical analysis 110
All measurements above were performed in triplicate and repeated at least three times. in both CKI treated and untreated cells from 0 to 48 hrs after treatment and observed a reduction in 118 glucose uptake (Fig. 1A) . The growth curves for both cell lines were relatively flat after CKI ratio at 24 and 48 hours after treatment (Fig. 1B) . HEPG2 cells had a lower energy charge (higher 131
[ADP]/[ATP] ratio) compared to MDA-MB-231 cells and after CKI treatment both cell lines showed 132 a decrease in energy charge, consistent with our previous measurements using a Figure S1 ). However the decrease in energy charge was earlier and much 135 more pronounced for HEPG2 cells compared to MDA-MB-231 cells.
136
The flip side of glucose consumption is the production of lactate via glycolysis, which is the initial 137 pathway for glucose metabolism. We therefore measured lactate production in order to determine if 138 the observed decreases in energy charge and glucose consumption were directly attributable to 139 reduced glycolytic activity. We measured intracellular lactate concentration in both CKI treated and 140 untreated cells at 24 and 48 hours after treatment (Fig. 1C) cell cycle, such as DNA replication.
147
Having validated the effect of CKI on cellular energy metabolism, we proceeded to examine the 148 perturbation of cell cycle and expression of cell cycle proteins, as these are energy intensive processes. 149 We had previously identified the cell cycle as a target for CKI based on transcriptome data from CKI 150 treated cells [4, 8] . We carried out cell cycle profiling on CKI treated and untreated cells using 
159
We also examined the levels of key proteins involved in the cell cycle pathway (Cyclin to have altered transcript expression by CKI (Fig. 2B ). Both cell lines showed similar results for all 163 five proteins, with decreased levels caused by CKI, and validated previous RNAseq data [4, 8] .
164
CCND1 regulaes the cell-cycle during G1/S transition. CDK-1 promotes G2-M transition, and regulates G1 progress and G1-S transition. CDK-2 acts at the G1-S transition to promote the E2F 166 transcriptional program and the initiation of DNA synthesis, and modulates G2 progression. TP53 167 acts to negatively regulate cell division. CTNNB1 acts as a negative regulator of centrosome 168 cohesion. Down-regulation of these proteins is therefore consistent with cell cycle 169 arrest/disregulation and the cell cycle result in Fig. 2A . These results indicate that CKI alters cell 170
cycle regulation consistent with cell cycle arrest. Cell cycle arrest is also an outcome that can result 171
from DNA damage such as DSBs [12] .
172
We had previously observed that DNA repair genes had lower transcript levels in CKI treated 173 cells [4, 8] , so hypothesised that this might result in increased numbers of DSBs. We measured the 174 expression of γ-H2AX in both cell lines (Fig. 3A) and found that it was only over-expressed at 48 175 hours in CKI treated HEPG2 cells. We also carried out localization of γ-H2AX using quantitative 176
immunofluorescence microscopy and determined that the level of γ-H2AX increased in nuclei of CKI 177 treated cells in both cell lines (Fig. 3B) . These results indicated an increase in DSBs as a result of 178 CKI treatment. In order to confirm if reduced expression of DNA repair proteins was correlated with 179 the increase in DSBs we measured levels of Ku70/Ku80 proteins in CKI treated cells (Fig. 3C) . an increased level of DSBs.
187
Effect of Oxymatrine, the principal alkaloid in CKI
188
Because CKI is a complex mixture of many plant secondary metabolites that may have many targets 189
and there is little known about its molecular mode of action, we examined the effects of the most 190 abundant single compound found in CKI, oxymatrine, on the most sensitive cell line, HEPG2.
191
Oxymatrine is an alkaloid that has previously been reported to have effects similar to CKI, so we 192 expected it might have an effect on one or more of our three validated pathways.
193
Oxymatrine, at 0.5 mg/ml which is equivalent to the concentration of oxymatrine in 2mg/ml CKI, 194 did not have an equivalent effect on the cell cycle compared to CKI (Fig. 4A vs Fig. 2A ).
195
Oxymatrine caused only minor changes to the cell cycle with small but significant increases in the 196
proportion of cells in G1-phase at 3 and 48 hours and a small but significant decrease in the
197
proportion of cells in S1-phase at 48 hours. Oxymatrine also caused a significant increase in the
198
proportion of cells undergoing apoptosis in HEPG2 cells, albeit at a lower level than CKI
199
(Supplementary Material, Figure 2 ).
200
Oxymatrine had no effect on H2AX levels in HEPG2 cells (Fig. 4B) . This was in stark contrast to 201 the effect of CKI (Fig. 3A) at 48 hours and indicated that oxymatrine alone had no effect on the 202 level of DSBs. 
206
Integration of results
207
The effect of CKI on cancer cells was validated in all three of our candidate pathways: cell cycle, CKI may also act through the synergistic effects of multiple compounds on multiple targets in our 212 candidate pathways. This possibility is consistent with the partial and minor effects of oxymatrine 213 on our candidate pathways. experiments. In our hands oxymatrine alone at 0.5mg/ml showed no effect on DSBs as judged by the 246 level of γ-H2AX after 24 or 48 hours.
247
Conclusions
248
CKI causes suppression of energy metabolism and DNA repair along with altered cell cycle
249
(summarized in Fig. 5 ). CKI has also previously been reported to induce apoptosis in cancer cells [4] . 250 The overarching question is if CKI has independent effects on these three pathways or if the primary 251 effect of CKI is through a single pathway that propagates effects to other, physiologically linked affected by oxymatrine and thus CKI. However oxymatrine alone had no effect on DNA repair and 257 boosted, rather than reduced the energy charge of the cell. Taken together, these results support a 258 model of many compounds/many targets [20] Medicine (GZYYGJ2017035) and The University of Adelaide -Zhendong Australia -China Centre 267
for Molecular Chinese Medicine.
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